Preceptis Medical today said it has launched its Hummingbird tympanostomy tube system for office-based pediatric ear tube procedures. The Maple Grove, Minn.–based company designed the device with an ergonomic design to allow for more efficient ear tube delivery in children. Get the full story on our sister site, Medical Tubing + Extrusion.
Otolaryngology/Ear, Nose & Throat (ENT)
GM Instruments announced today that it partnered with Sensonics to develop devices for the quantitative assessment of nasal and oral function. The companies tout the first-of-its-kind partnership as a bringing together of sensory and engineering expertise for evaluating and treating nasal and oral diseases. Get the full story at our sister site, Drug Delivery Business News.
Lyra Therapeutics (NSDQ:LYRA) announced today that it entered into a strategic partnership with LianBio for its LYR-210 treatment for chronic rhinosinusitis. Watertown, Mass.–based Lyra, which develops the LYR-210 therapeutic to be locally delivered by its proprietary XTreo platform, could receive up to $135 million in total payments through the strategic partnership and exclusive license agreement […]
Noveome Biotherapeutics announced that it entered a commercial license agreement to use SipNose’s proprietary drug delivery device. Yokneam, Israel–based SipNose develops its intranasal Cribriform Targeted Device (CT6), which, under the agreement, was licensed to Noveome to deliver the Pittsburgh-based company’s ST266 biologic to the central nervous systems, according to a news release. Get the full story at our […]
Intersect ENT (NSDQ:XENT) announced today that it received CE mark approval for its Propel Contour sinus implant. Menlo Park, Calif.-based Intersect ENT designed its Propel Contour sinus implant to maintain patency and reduce inflammation while conforming to the sinus ostia (openings) through mechanical support and steroid delivery where needed to optimize sinus surgery outcomes. Propel […]
Lyra Therapeutics (NSDQ:LYRA) shares finished up on the day despite first-quarter results that missed the consensus earnings forecast. The Watertown, Mass.-based chronic rhinosinusitis (CRS) treatment developer posted losses of -$7.8 million, or -60¢ per share for the three months ended March 31, 2021, for a -84.4% bottom-line slide. Lyra’s EPS of -60¢ came in 48¢ behind […]
Intersect ENT (NSDQ:XENT) today said it has appointed Mark Alley as VP of sales, effective May 10. Alley most recently served as chief commercial officer at Levita Magnetics. He has more than 20 years of commercial and sales experience and has held numerous leadership roles at Stryker ENT, Spirox and Acclarent. “Mark has a reputation for […]
Lyra Therapeutics (NSDQ:LYRA) presented positive results from a Phase 2 study of its therapeutic for treating chronic rhinosinusitis (CRS). Watertown, Mass.-based Lyra’s Phase 2 Lantern study evaluated its LYR-210 long-acting product for CRS, which is administered in-office to deliver a sustained release for up to six months as a non-invasive alternative to surgery for patients who […]
Envoy Medical announced today that its Esteem middle ear implant showed statistically significant improvements in postoperative results. White Bear Lake, Minn.–based Envoy’s Esteem osseointegrated active middle ear implant (AMEI) is for patients with moderate-to-severe sensorineural hearing loss who have failed to benefit from traditional amplification like hearing aids. Esteem is the first and only fully […]
With the use of anti-inflammatory drugs constituting the standard of care for treating rhinosinusitis, Lyra Therapeutics sees an opportunity. Whatever treatments are out there for the disease in which cavities around the nasal passages are inflamed, they leave room for improvement. “We focused on chronic rhinosinusitis because it’s an area that has been ignored,” Lyra […]
Frequency Therapeutics (Woburn, Mass.) recently announced data related to its experimental FX-322 drug. The small Phase 1/2 study, published in Otology & Neurotology, found hearing improvements in adults with age-related sensorineural hearing loss. At present, there are no FDA-approved drugs for preventing or restoring such hearing loss. However, administering steroids can facilitate recovery of hearing […]